Exploring the Efficacy and Safety of Belimumab in the Treatment of Sys-temic Lupus Erythematosus(SLE)
Objective To investigate the therapeutic effect and safety of systemic lupus erythematosus(SLE)with the application of belimumab.Methods 60 patients with systemic lupus erythematosus admitted to Linyi Central Hospital from March 2021 to August 2023 were randomly selected as the study objects and randomly divided into single group and combined group by drawing lot,with 30 cases in each group.The single group received standard treatment,and the combined group received beliuzumab on the basis of the single group.The therapeutic effect,immune indexes,hor-mone dose,disease activity index score and adverse reactions were compared between the two groups.Results The ef-fective rate of combination group was 83.33%,which was higher than that of single group(36.67%),and the difference was statistically significant(χ2=5.164,P<0.05).After treatment,the level of complement C3 and complement C4 in combination group was higher than that in single group,and IgG level,hormone dose and disease activity index score were lower than that in single group,and the difference was statistically significant(all P<0.05).There was no statisti-cally significant difference in the incidence rate of adverse reactions between the two groups(P>0.05).Conclusion Be-liuzumab treatment can effectively improve the therapeutic effect of patients,improve their immune indicators,reduce the hormone dose of patients,and reduce the disease activity index,and this combination therapy does not increase the risk of adverse reactions in patients,and its safety is high.
Systemic lupus erythematosusBelimumabHormone doseImmune indexDisease activity index
NETL
NSTL
万方数据
维普
